Increased Expression of Yes-Associated Protein 1 in Hepatocellular Carcinoma with Stemness and Combined Hepatocellular-Cholangiocarcinoma

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Kim, Gi Jeong ^a   Kim, Hyunki ^a   Park, Young Nyun ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CYTOKERATIN 19; EPITHELIAL CELL ADHESION MOLECULE; PROTEIN KINASE YES; THY 1 ANTIGEN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN 1;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE CARE; PROTEIN EXPRESSION; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CHOLANGIOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; PHOSPHOPROTEINS; STATISTICS, NONPARAMETRIC;

EID: 84884560531     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075449     Document Type: Article

References (33)

1. Jemal A, Center MM, DeSantis C, Ward EM, (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907.
2. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L, (1985) Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 55: 124-135.
3. Theise ND, Nakashima O, Park YN, Nakamura Y (2010) Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: International agency for research on cancer. pp. 225-227.
4. Zhu Z, Hao X, Yan M, Yao M, Ge C, et al. (2010) Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 126: 2067-2078.
5. Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, et al. (2013) Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 57: 1484-1497.
6. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, et al. (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13: 153-166.
7. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, et al. (2010) miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7: 694-707.
8. Ma YC, Yang JY, Yan LN (2013) Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis. Eur J Gastroenterol Hepatol.
9. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, et al. (2011) Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 54: 1707-1717.
10. Shan YF, Huang YL, Xie YK, Tan YH, Chen BC, et al. (2011) Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status. Med Oncol 28: 1012-1016.
11. Okamura D, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, et al. (2008) Ezrin expression is associated with hepatocellular carcinoma possibly derived from progenitor cells and early recurrence after surgical resection. Mod Pathol 21: 847-855.
12. Lee JH, Chung GE, Yu SJ, Hwang SY, Kim JS, et al. (2011) Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol 45: 69-75.
13. Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, et al. (2012) Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 19: 2869-2876.
14. Huang J, Wu S, Barrera J, Matthews K, Pan D, (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122: 421-434.
15. Kango-Singh M, Singh A, (2009) Regulation of organ size: insights from the Drosophila Hippo signaling pathway. Dev Dyn 238: 1627-1637.
16. Lian I, Kim J, Okazawa H, Zhao J, Zhao B, et al. (2010) The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev 24: 1106-1118.
17. Liu AM, Xu MZ, Chen J, Poon RT, Luk JM, (2010) Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin Ther Targets 14: 855-868.
18. Halder G, Dupont S, Piccolo S, (2012) Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol 13: 591-600.
19. Liu AM, Xu Z, Luk JM, (2012) An update on targeting Hippo-YAP signaling in liver cancer. Expert Opin Ther Targets 16: 243-247.
20. Lam-Himlin DM, Daniels JA, Gayyed MF, Dong J, Maitra A, et al. (2006) The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. Int J Gastrointest Cancer 37: 103-109.
21. Lee KP, Lee JH, Kim TS, Kim TH, Park HD, et al. (2010) The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A 107: 8248-8253.
22. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, et al. (2006) The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 49: 138-151.
23. Yuan RH, Jeng YM, Hu RH, Lai PL, Lee PH, et al. (2011) Role of p53 and beta-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg 15: 321-329.
24. Coulouarn C, Cavard C, Rubbia-Brandt L, Audebourg A, Dumont F, et al. (2012) Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFbeta signaling pathways. Carcinogenesis 33: 1791-1796.
25. Yu XH, Xu LB, Zeng H, Zhang R, Wang J, et al. (2011) Clinicopathological analysis of 14 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 10: 620-625.
26. Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M, (1995) Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol 26: 956-964.
27. Koh KC, Lee H, Choi MS, Lee JH, Paik SW, et al. (2005) Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg 189: 120-125.
28. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, et al. (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 103: 12405-12410.
29. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
30. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, et al. (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115: 4576-4585.
31. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, et al. (2010) Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 101: 1279-1285.
32. Kang W, Tong JH, Chan AW, Lee TL, Lung RW, et al. (2011) Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res 17: 2130-2139.
33. Wang L, Shi S, Guo Z, Zhang X, Han S, et al. (2013) Overexpression of YAP and TAZ Is an Independent Predictor of Prognosis in Colorectal Cancer and Related to the Proliferation and Metastasis of Colon Cancer Cells. PLoS One 8: e65539.